ArticleTranslational pediatrics2025
Epigallocatechin gallate improves insulin sensitivity in rats experiencing catch-up growth after being small for gestational age by upregulating PDX1 expression.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Increasingly small for gestational age (SGA) newborns is an issue all over the world. In the early life of SGA, catch-up growth (CUG) may appear with elevated insulin resistance risk. Epigallocatechin gallate (EGCG) preserves therapeutic potential in metabolic disorders, however, the mechanism of EGCG's protective effects remains largely unclear. Our purpose is to investigate EGCG on insulin sensitivity during CUG in rats recovered from being SGA and to explore the potential underlying mechanism. Methods: We established a food restriction-based SGA rat model and selected CUG rats for EGCG treatment. Hyperinsulinemic-euglycemic clamp technique was used to measure glucose and insulin sensitivity. Furthermore, we assessed the apoptosis of islet pancreatic cells through TdT-mediated dUTP Nick-End Labeling (TUNEL) assays. Subsequently analyzed pancreatic PDX1 and proliferation-related protein PCNA, CDK4 and cyclin D2 expression by Western blot. Finally, we established a high glucose (HG)-induced insulin resistance MIN6 pancreatic β cell model. PDX1 knockdown was used to determine whether EGCG protect pancreatic β cell from HG damage by regulating PDX1 expression. Results: We found that EGCG treatment significantly ameliorated CUG rats exhibiting insulin resistance by regulating pancreatic cell apoptosis and proliferation. PDX1 expression was significantly decreased with pancreas damage in CUG rats, while EGCG upregulates PDX1 expression correlated with improved insulin sensitivity in pancreatic tissues. In vitro assays further validated PDX1 is downregulated in HG induced pancreatic β cell insulin resistance model, while EGCG promoted β cell survival rate and inhibited apoptosis by regulating PDX1 expression. Conclusions: EGCG may enhance insulin sensitivity in CUG rats by upregulating pancreatic PDX1 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.